Pharmacon Nuclear Inc is categorized under Operators of Nonresidential Buildings in Atlanta, GA and active since 1976.
Pharmacon Nuclear Inc was established in 1976, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Operators of Nonresidential Buildings business, which does work in the B2B market, and is classified as a Operators of Nonresidential Buildings, under code number 531312 by the NAICS.
If you are seeking more information, feel free to contact Claude Tatro at the company’s single location by writing to 3812 Mcelroy Road, Atlanta, Georgia GA 30340 or by phoning (678) 209-0409. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Pharmacon Nuclear Inc |
| Contact Person: | Claude Tatro |
| Address: | 3812 Mcelroy Road, Atlanta, Georgia 30340 |
| Phone Number: | (678) 209-0409 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 1976 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Operators of Nonresidential Buildings |
| SIC Code: | 6512 |
| NAICS Code: | 531312 |
| Share This Business: |
Pharmacon Nuclear Inc was started in 1976 to provide professional Operators of Nonresidential Buildings under the SIC code 6512 and NAICS code 531312. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Claude Tatro for inquiries that concern Pharmacon Nuclear Inc by calling the company number (678) 209-0409, as your correspondence is most welcome. Additionally, the physical location of the single location of Pharmacon Nuclear Inc can be found at the coordinates 33.90317,-84.265831 as well as the street address 3812 Mcelroy Road in Atlanta, Georgia 30340.
For its online presence, you may visit Pharmacon Nuclear Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.